Post by EveningOfTheDay on Dec 28, 2015 1:37:44 GMT -5
I think the answer is a lot simpler. Sanofi probably realized from day one Afrezza would take time. They might not have know how much, but certainly now they realized hit will take lots of time an money too. Lantus is their bread and butter and they badly need Toujeo to succeed as too minimize the loss of market share when Lantus goes off patent. Hence, they have poured all their efforts on Toujeo in the thought that only Toujeo could soften the blow.
The real question to me is, now that they have realized Afrezza will take considerable time, effort and money, perhaps more than they initially thought, and now that it is clear Toujeo will not carry them to the promise land, will they heavily turn to the potential of Afrezza or will they continue they very gradual approach and push other drugs harder. They could still think Toujeo is their short term best option and double down on it, or they could try to find some other thing. In any case I do not think they will abandon Afrezza since it would not make much sense, but we will be learning about it very soon.
The real question to me is, now that they have realized Afrezza will take considerable time, effort and money, perhaps more than they initially thought, and now that it is clear Toujeo will not carry them to the promise land, will they heavily turn to the potential of Afrezza or will they continue they very gradual approach and push other drugs harder. They could still think Toujeo is their short term best option and double down on it, or they could try to find some other thing. In any case I do not think they will abandon Afrezza since it would not make much sense, but we will be learning about it very soon.
